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Attributable to their strong electrical activity, neurons have long been seen as the main
determinants of brain function. Over the last decades, however, this view changed dramatically. A
variety of specific roles have been assigned to different types of glial cells. Astrocytes constitute the
link between the vascular system and neighboring neurons. They determine ion and transmitter
homeostasis, metabolism and neuronal activity. Oligodendrocytes form the myelin sheath. They
determine fast signal propagation, timing, and synchronicity. Microglial cells comprise not only
the innate immune system of the brain, they also actively regulate synaptogenesis and removal
of supra-numerous synapses. In general, microglial cells are quite uniformly distributed across
different brain regions.
Looking at the system level of the brain, we have to take into account that the description of
THE astrocyte as a uniform cell type is clearly outdated. Exploring astrocyte heterogeneity based
on localization, function, age, and condition is becoming a major endeavor to fully understand
brain function (Oberheim et al., 2012; Bayraktar et al., 2015; Schitine et al., 2015; Bribián et al.,
2016). Astrocyte heterogeneity is not only a phenomenon between different brain regions such as
cortex, hippocampus, or cerebellum, but also within a given territory. In the healthy, adult cortex
the astroglial intermediate filament protein GFAP (glial fibrillary acidic protein) can be hardly
detected in most of the astrocytes and only those contacting brain vasculature express significant
levels (Figure 1A). In contrast, in the hippocampus almost all astrocytes exhibit a strong and
steady expression (Figure 1C). Another striking example of astroglial diversity is reflected by the
expression of various transporters or transmitter receptors. Perisynaptic appendages of cerebellar
Bergmann glia aremorphologically hard to distinguish from hippocampal astrocyte processes at the
ultrastructural level. But, while the first glial cell type is characterized by high levels of AMPA-type
glutamate receptor expression, the latter is completely devoid of these receptors (Matthias et al.,
2003; Saab et al., 2012). Similar to the heterogeneity of astrocytes within or between given brain
regions, we also have to consider a heterogeneity within a single cell given by the highly complex
and polarized morphology of astrocytes bridging the gap from the brain capillaries to the neuronal
synapses.
Taking into account that a cortical astrocyte contacts up to 600 dendrites, the broad and
extended impact of astrocytes on neuronal plasticity becomes evident (Heller and Rusakov, 2015).
It is not too tempting to speculate that this feature of astrocytes is less involved in the integration
of neuronal signals rather than in modulation and synchronization of neuronal network activity of
adjacent microcircuit domains of defined central nervous system (CNS) regions. While astrocytes
can directly affect local synapses in the close neighborhood (<20 µm), the gap junction-coupled
astroglial syncytium can bridge neighboring microcircuits (Figure 2; Navarrete and Araque, 2010;
Navarrete et al., 2014).
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FIGURE 1 | Astrocytes and microglia in the forebrain. Distinct subtypes of astrocytes are present throughout the brain, while microglial cells seem to be more
homogenously distributed. In the cortex only astrocytes in close contact to blood capillaries express significant levels of GFAP (A), while all astrocytes are closely
intermingled with adjacent neurons (A) or microglia (B). In contrast, in the hippocampus all astrocytes express GFAP (C). They are also in close contact to neurons (B)
and microglial cells (D). Comparison of GFAP staining (D) with EGFP expression in (B) of TgN (GFAP-EGFP)GFEC transgenic mice reveals only in the latter the fine
arborization of perisynaptic and perivascular astrocytic processes. The square in (B) indicates the magnified view that is schematically depicted in Figure 2. Scale
bars indicate 20 µm.
Common to all glial cells is the expression of a similar
set of ionotropic or metabotropic receptors as their adjacent
neuronal counterparts. And indeed, glutamate, GABA and ATP
have been studied intensively, not only as classical transmitters
but also as important molecular entities that constitute various
forms of bidirectional communication among neurons and glia.
Quite surprisingly, however, the most abundant metabotropic
G-protein coupled receptor of the brain is sensitive to none of
these important molecules. It is the cannabinoid type I (CB1)
receptor which is expressed at variable levels on almost all cells
of the CNS and is activated endogenously by two metabolites
of arachidonic acid, N-arachidonoyl-ethanolamine (anandamide,
AEA) and the more potent 2-arachidonoyl-glycerol (2-AG;
Stella, 2010; Boorman et al., 2016). More commonly known
is their relative which is found in Cannabis sativa, 19-
tetrahydrocannabinol (THC), the main constituent of marijuana.
Like THC, also AEA and 2-AG are psychoactive. While the
CB1 receptor is expressed quite uniformly, the cannabinoid
type II (CB2) receptor is expressed at low levels, but strongly
activated in microglia or endothelial cells in CNS pathologies
(Herkenham et al., 1990; Piomelli, 2003; Núñez et al., 2004;
Atwood and Mackie, 2010; Zhang et al., 2014; Boorman et al.,
2016; Oliveira da Cruz et al., 2016). The lipophilic nature of
the endocannabinoids (ECB) together with the broad expression
of the CB1 receptor results in more generalized functions in
all brain regions. Dependent on the region-specific pattern of
neurons and glial cells, activation of the endogenous cannabinoid
signaling system can affect numerous neural circuits broadly,
ranging from cognition to eating or motor behavior. Here,
we would like to discuss the specific functions of CB1 and
CB2 receptors on the two glial cell types, astrocytes and
microglia in respect to the more recently described cellular
heterogeneity.
Frequent use of marijuana by distinct human populations had
provided strong insight into the function of the ECB system,
the receptors as well as their ligands. Cannabis users exhibited
significant distortions of their working and declarative memory.
The impaired reality monitoring further resulted in a distinct
susceptibility to false memories (Riba et al., 2015). In more
controlled animal experiments using rodents, THC induced
a combination of physiological/behavioral changes including
spontaneous activity, catalepsy, hypothermia, and analgesia
(Little et al., 1988; Howlett et al., 2002). Due to distinct expression
of the respective receptors, CB1 and CB2, ECB signaling can
determine brain functions at different levels. While expression of
the CB1 receptor is held responsible for the more psychoactive
behavior after activation, the CB2 receptor is more involved in
anti-inflammatory processes (Buckley et al., 2000; Mackie, 2005;
Buckley, 2008).
In contrast to excitatory transmitters, ECBs are generated and
released from activated post-synaptic dendritic terminals and
evoke a diversity of complex signaling routes involving neurons
and adjacent glia (see Figure 2): (1) They act retrogradely at
neuronal pre-synapses to control further transmitter release,
resulting in suppression of excitation (Navarrete et al., 2014).
(2) Simultaneously activated CB1 receptors on perisynaptic
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FIGURE 2 | Close interactions of perisynaptic astroglial and microglial processes with the synaptic elements of adjacent neurons. The boxed regions
indicate specific sites of neuron-glial interactions. Perisynaptic astroglial processes (green) express the cannabinoid receptors CB1 (cyan), while microglial processes
both, CB1 (cyan) and CB2 (blue) receptors in close contact to postsynaptic ECB (yellow) release sites (A). Astrocytes respond to ECB via CB1 receptors with an
increase of intracellular Ca2+ (purple). This intracellular Ca2+ rise spreads (pink arrows) through the astrocyte towards distant synapses (B), where Ca2+-evoked
release of the gliotransmitter glutamate (orange) affects neuronal physiology via presynaptic metabotropic glutamate receptors (mGluR1, brown), and generates a
persistent synaptic change (B). In addition, the Ca2+ wave can be propagated through the gap junction-coupled astroglial syncytium (gj, light green) where on even
more distant perisynaptic processes gliotransmitters (glutamate) are released as response to postsynaptic ECB liberation. Subsequently, gliotransmitters can act on
postsynaptic NMDA receptors (C, brown) inducing slow inward currents.
astroglial processes, however, cause an intracellular Ca2+
release from internal stores via the Gq/11 / phospholipase
C / inositol trisphosphate pathway (Navarrete and Araque,
2008, 2010) and stimulate additional release of gliotransmitters,
preferentially glutamate, triggering presynaptically localized
metabotropic glutamate receptors (Figure 2B) as well as
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postsynaptic NMDA receptors (Figure 2C). The depression
of excitatory neurotransmission by ECB-evoked presynaptic
inhibition of neurotransmitter release impairs spatial working
memory (Misner and Sullivan, 1999; Carlson et al., 2002;
Takahashi and Castillo, 2006; Bajo et al., 2009; Schoeler and
Bhattacharyya, 2013; Schoeler et al., 2016). This inhibiting
signaling only works over short distances of less than 20 µm
(Navarrete and Araque, 2010). In contrast, ECB-evoked signals
in adjacent astroglial processes can affect remote synapses by
using the gap junction-coupled astroglial syncytium as a bridge
(Navarrete and Araque, 2010; Navarrete et al., 2014; Gómez-
Gonzalo et al., 2015; Figure 2). Interestingly, the CB1-mediated
astroglial release of glutamate can cause both, potentiation as
well as depression of neuronal transmission. In the hippocampus,
activation of postsynaptic NMDA receptors (Figure 2C) induces
slow inward currents in CA1 pyramidal neurons (Navarrete and
Araque, 2008; Navarrete et al., 2013, 2014), while presynaptic
NMDA receptor activation causes spike timing-dependent
depression (Min and Nevian, 2012). Presynaptic activation of
type 1 metabotropic glutamate receptors (mGluR1) coincident
with NO signaling from the postsynapse induces long-lasting
synaptic potentiation. mGluR-mediated activation of presynaptic
protein kinase C enhances transmitter release persistently
(Gómez-Gonzalo et al., 2015). The ECB signaling on astrocytes
induces highly selective, circuit-specific modulation of synaptic
transmission. In the striatum the astroglial glutamate release
acts only on the same subtype of medium spiny neuron (MSN)
from which the ECB was released (Martin et al., 2015). The
neuronal subtypes can be distinguished by their dopamine
receptor expression (D1 and D2). The ECB releasing MSN and
the glia-modified neuron have both to express either the D1 or
the D2 receptor; no potentiation is detected if oneMSN expresses
the D1 and the other the D2 receptor or vice versa.
In the hippocampus, the maintenance of epileptic discharges
is reduced when the neuron-to-astrocyte communication via
CB1 receptor activation is pharmacologically blocked (Coiret
et al., 2012). Surprisingly, despite the fact that the CB1
receptor is widely expressed on all hippocampal cells, it
was only the astrocyte specific deletion of the CB1 receptor
gene that completely eliminated THC-induced depression (Han
et al., 2012). In detail, THC stimulates glutamate release from
astrocytes by activation of its CB1. The adjacent neuron then
shows long-term depression (LTD) by internalizing its AMPA-
type glutamate receptors. At the behavioral level, a severe
impairment of spatial working memory is observed (Han
et al., 2012). But CB1 receptor expression in astrocytes is
not restricted to processes at synapses. Astrocytes are also in
close contact to blood vessels where the CB1 receptor has
been localized to the perivascular endfeet as well (Rodriguez
et al., 2001). The functional meaning for this spatial separation
is not yet clear. Obviously, the function of the astroglial
CB1 receptor is not restricted to neuronal transmission. By
controlling local cerebral blood flow, astrocytes adjust the
energy supply within a single neuronal microcircuit or even
linking adjacent networks, a phenomenon that has been
termed neurovascular coupling (Stella, 2010). The modulation
of neurovascular coupling by targeting CB1 receptors could
become important in novel strategies to combat the sequelae
of ischemic insults. Similarly, it will be highly interesting to
assign distinct roles of CB1 receptors which are expressed on
perisynaptic processes or at the perivascular endfeet to specific
behaviors. So far, only learning paradigms have been tested
which would favor more the influence of CB1 receptors at the
synapse, e.g., the spatial working memory in the hippocampus
investigated by Han et al. (2012). It would now be very
interesting, though technically challenging, to perform two-
photon imaging of the neurovascular unit in experimental
mice under different conditions of genetic or pharmacological
CB1 receptor modulation and cognitive stress. Curiously, these
experiments could be done by the same genetically modified
mice (GFAP-CreERT2 × floxed CB1) that Han et al. (2012)
had investigated. The GFAP-CreERT2 mouse line shows a more
efficient recombination of cortical astrocytes that are part of
the neurovascular unit and contact the capillaries (Jahn et al.,
2015).
Another important glial cell type involved in ECB signaling
are microglia. Their processes that are also in close contact
with synapses and blood vessels express both, CB1 and CB2
receptors (Núñez et al., 2004; Maresz et al., 2005; Cabral
et al., 2008; Figures 1B,D). While these innate immune cells
of the CNS express only very low levels of the CB1 receptor,
their major player of the ECB signaling game is the CB2
receptor. Under resting conditions the CB2 receptor is weakly
expressed as well, but expression levels are highly responsive
and get strongly increased upon neuroinflammatory processes
associated with brain pathologies (Maresz et al., 2005; Cabral
et al., 2008; Atwood and Mackie, 2010; Mecha et al., 2015;
Schmole et al., 2015). Interestingly, in contrast to the CB1
receptor, selective agonists of the CB2 receptor are not psycho-
active. Instead, the most potent ECB, 2-AG, exhibits strong
neuroprotective effects in acute CNS injuries (Ashton and Glass,
2007; Arevalo-Martin et al., 2010). Triggering the microglial
CB2 receptor reduces the release of pro-inflammatory cytokines
by activated microglia. And similar to astrocytes, there is also
a distinct population of microglia that surround the brain
capillaries. The perivascular microglia closely interact with the
capillary-forming endothelial cells that express CB2 receptors
as well. And indeed, pharmacologically selective stimulation
of the CB2 receptor stabilized and enhanced the efficacy
of the blood-brain barrier (BBB), thereby dampening the
consequences of neuroinflammatory injuries (Ramirez et al.,
2012). In addition, activation of CB2 receptors signaled into
the luminal side of the endothelium and reduced the homing
of leukocytes to even further rescue an inflammatory response
by recruiting peripheral immune cells, as it could be visualized
by repeated long-term two-photon microscopy (Ramirez et al.,
2012).
OUTLOOK
Obviously ECB signaling in the brain comes in different glial
flavors. While CB1 receptors of perisynaptic astroglial process
strongly affect different forms of neuronal plasticity, microglial
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and endothelial CB2 receptors provide efficient neuroprotection
by reducing neuroinflammatory processes including tightening
of the BBB. However, important research questions remain for
the future:
What is the function of astroglial CB1 receptors at the
perivascular endfeet? In this context it is particularly intriguing
that CB1 receptors are not only widely expressed throughout the
brain on the cell surface, but also on mitochondrial membranes.
Could it be that ECB signaling represents a major regulatory
system that regulates energy demands in the brain, acting on
a variety of different levels from regulating glucose uptake at
the brain vasculature to fine-tuning oxidative phosphorylation in
mitochondria?
Does the low level of the CB2 receptor onmicroglia contribute
to normal brain functions? Are there synergistic interactions of
the individual components of ECB signaling on different cell
types? More cell-specific genetic manipulations of ECB signaling
are required. In particular, specific receptor targeting as well
as imaging approaches, that will help to unravel the diversity
of intracellular signaling cascades, are necessary. Innovative
combination of imaging and genetic approaches in vivo will pave
the way for exciting new findings.
MATERIALS AND METHODS
This study was carried out at the University of Saarland (Center
for Integrative Physiology and Molecular Medicine, CIPMM)
in strict accordance with recommendations of European
and German guidelines for the welfare of experimental
animals. Animal experiments were approved by Saarland
state’s “Landesamt für Gesundheit und Verbraucherschutz” in
Saarbrücken/Germany (animal license number: 71/2010). No
vulnerable populations (minors, persons with disabilities or
endangered animal species) were involved.
Mouse breeding and animal experiments were performed
at the animal facility and the research labs of the CIPMM.
For the immunohistochemical analysis heterozygous 8-week-old
TgN(hGFAP-EGFP)GFEC mice were used (Hirrlinger et al.,
2005). Mouse perfusion, tissue fixation and vibratome slice
preparation (40 µm) were performed as described previously
(Huang et al., 2014). For immunohistochemistry, the following
antibodies were used: polyclonal rabbit anti-GFAP (1:1000, Dako
Cytomation, Glostrup, Denmark) and anti-Iba1 (1:1000, Wako,
Richmond, USA), monoclonal mouse anti-NeuN (1:500, Merck
Millipore, Darmstadt, Germany) and anti-rabbit/mouse antibody
conjugated Alexa543/633 (1:2000, Invitrogen, Grand Island NY,
USA). The transgenic EGFP signal was directly recorded without
additional antibody enhancement. Confocal images were taken
by a laser-scanning microscope (LSM-710, Zeiss), processed
with ZEN software (Zeiss) and displayed as maximum intensity
projections. Figures presented in this work were modified with
image processing tools of ImageJ (Fiji, www.fiji.sc).
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